|
In Session with Daphne Holt, MD, PhD: Brain Imaging Work and Its Potential Practical Applications to Treat Mental Disease
|
Dr. Holt is Assistant Professor at Harvard Medical School as well as Associate Psychiatrist and Associate Director of the First Episode and Early Psychosis Program at Massachusetts General Hospital in Boston. In her research, Dr. Holt applies neuroimaging methods, such as functional and structural magnetic resonance imaging and electroencephalography, to the study of the neural basis of emotional function and social behavior in healthy people and patients with psychiatric disorders, particularly schizophrenia.
|
9/1/2010
|
|
In Session with David Mrazek, MD: Clinical Implementation of Pharmacogenomic Testing
|
Dr. Mrazek is Chair of the Department of Psychiatry and Psychology at the Mayo Clinic and a Professor of Psychiatry and Pediatrics at the Mayo Clinic College of Medicine in Rochester, Minnesota.
|
7/30/2010
|
|
In Session with Anil Malhotra, MD: Pharmacogenetics of Schizophrenia
|
Dr. Malhotra is the Director of Psychiatry Research at the Zucker Hillside Hospital in Glen Oaks, New York, and professor of psychiatry at the Albert Einstein College of Medicine in Bronx, New York. His research group focuses on identifying the biologic underpinnings of schizophrenia and the mechanism of action of antipsychotics. They have identified numerous genes associated with increased risk for the disorder; determined their relationship with important clinical manifestations of illness, including cognitive impairment; and begun to examine the role of genetic factors in predicting individual responses to pharmacologic treatment.
|
6/23/2010
|
|
In Session with Kiki Chang, MD: Bipolar Disorder in Children and Adolescents
|
Dr. Chang is associate professor of Psychiatry and Behavioral Sciences in the Division of Child Psychiatry at the Stanford University School of Medicine in California. He is director of the Pediatric Bipolar Disorders Clinic and Research Program, where he specializes in pediatric psychopharmacology and treatment of depression and bipolar disorder in children and adolescents. Dr. Chang’s research includes brain imaging, genetics, and medication and psychotherapy trials.
|
3/25/2010
|
|
In Session with Daniel Weintraub, MD: Psychiatric and Cognitive Complications of Parkinson’s Disease and Dementia with Lewy Bodies
|
Dr. Weintraub is Associate Professor of Psychiatry and Fellow at the Institute of Aging at the University of Pennsylvania in Philadelphia. His areas of research interest include the psychiatric and cognitive complications of Parkinson’s disease. Dr. Weintraub recently completed a 5-year Career Development Award from the National Institute of Mental Health titled “Depression Diagnosis and Treatment in Parkinson Disease.” In addition, he was coordinating investigator for a multi-site, international, industry-sponsored study of the frequency and correlates of impulse control disorders in Parkinson’s disease.
|
3/9/2010
|
|
In Session with Daniel Weintraub, MD: Psychiatric and Cognitive Complications of Parkinson’s Disease and Dementia with Lewy Bodies
|
Dr. Weintraub is Associate Professor of Psychiatry and Fellow at the Institute of Aging at the University of Pennsylvania in Philadelphia. His areas of research interest include the psychiatric and cognitive complications of Parkinson’s disease. Dr. Weintraub recently completed a 5-year Career Development Award from the National Institute of Mental Health titled “Depression Diagnosis and Treatment in Parkinson Disease.” In addition, he was coordinating investigator for a multi-site, international, industry-sponsored study of the frequency and correlates of impulse control disorders in Parkinson’s disease.
|
3/9/2010
|
|
In Session with Norman R. Relkin, MD, PhD: Alzheimer’s Disease: Potential Therapies, Vaccines,
and New Discoveries on the Horizon
|
Dr. Relkin is associate professor of Clinical Neurology and Neuroscience at Weill Cornell Medical College, attending neurologist at New York Presbyterian–Weill Cornell Hospital, and founding director of the Weill Cornell Memory Disorders Program. His research has led to improvements in the diagnosis, treatment, and prevention of Alzheimer’s disease and other forms of dementia. His work on genetics, biomarkers, and brain imaging has improved prediction and differential diagnosis of dementia.
|
2/8/2010
|
|
In Session with Norman R. Relkin, MD, PhD: Alzheimer’s Disease: Potential Therapies, Vaccines,
and New Discoveries on the Horizon
|
Dr. Relkin is associate professor of Clinical Neurology and Neuroscience at Weill Cornell Medical College, attending neurologist at New York Presbyterian–Weill Cornell Hospital, and founding director of the Weill Cornell Memory Disorders Program. His research has led to improvements in the diagnosis, treatment, and prevention of Alzheimer’s disease and other forms of dementia. His work on genetics, biomarkers, and brain imaging has improved prediction and differential diagnosis of dementia.
|
2/8/2010
|
|
In Session with Daniel Weintraub, MD: Psychiatric and Cognitive Complications of Parkinson’s Disease and Dementia with Lewy Bodies
|
Dr. Weintraub is Associate Professor of Psychiatry and Fellow at the Institute of Aging at the University of Pennsylvania in Philadelphia. His areas of research interest include the psychiatric and cognitive complications of Parkinson’s disease.
|
2/4/2010
|
|
In Session with Daniel Weintraub, MD: Psychiatric and Cognitive Complications of Parkinson’s Disease and Dementia with Lewy Bodies
|
Dr. Weintraub is Associate Professor of Psychiatry and Fellow at the Institute of Aging at the University of Pennsylvania in Philadelphia. His areas of research interest include the psychiatric and cognitive complications of Parkinson’s disease.
|
2/4/2010
|
|
In Session with Stephen M. Stahl, MD, PhD: The Future of Novel Drug Discovery in CNS
|
Dr. Stahl is adjunct professor of psychiatry at the University of California San Diego and chairman of the Neuroscience Education Institute. He was recently elected as an Honorary Visiting Fellow in the department of psychiatry at Cambridge University (UK). Of his many affiliations and accomplishments, Dr. Stahl serves as a fellow of the American College of Neuropsychopharmacology as well as the International College of Neuropsychopharmacology, where he was formerly vice president. Dr. Stahl’s major interests are dedicated to producing and disseminating educational information about diseases and their treatments in psychiatry and neurology, with a special emphasis on multimedia, the internet, and teaching how to teach.
|
1/8/2010
|
|
In Session with Stephen M. Stahl, MD, PhD: The Future of Novel Drug Discovery in CNS
|
Dr. Stahl is adjunct professor of psychiatry at the University of California San Diego and chairman of the Neuroscience Education Institute. He was recently elected as an Honorary Visiting Fellow in the department of psychiatry at Cambridge University (UK). Of his many affiliations and accomplishments, Dr. Stahl serves as a fellow of the American College of Neuropsychopharmacology as well as the International College of Neuropsychopharmacology, where he was formerly vice president. Dr. Stahl’s major interests are dedicated to producing and disseminating educational information about diseases and their treatments in psychiatry and neurology, with a special emphasis on multimedia, the internet, and teaching how to teach.
|
1/8/2010
|
|
In Session with Gordon Parker, MB BS, MD, PhD, DSc, FRANZCP: Antidepressants on Trial: How Valid is the Evidence?
|
Dr. Parker is Scientia Professor of Psychiatry at the University of New South Wales (UNSW) and Executive Director of the Black Dog Institute in Sydney, Australia. He was formerly Head of the School of Psychiatry at UNSW and Director of the Division of Psychiatry at Prince of Wales and Prince Henry Hospitals. An active researcher, Dr. Parker has focused on modeling psychiatric conditions (depressive, bipolar, and personality disorders) and examining causes, mechanisms, and treatments for mood disorders.
|
9/17/2009
|
|
In Session with Gordon Parker, MB BS, MD, PhD, DSc, FRANZCP: Antidepressants on Trial: How Valid is the Evidence?
|
Dr. Parker is Scientia Professor of Psychiatry at the University of New South Wales (UNSW) and Executive Director of the Black Dog Institute in Sydney, Australia. He was formerly Head of the School of Psychiatry at UNSW and Director of the Division of Psychiatry at Prince of Wales and Prince Henry Hospitals. An active researcher, Dr. Parker has focused on modeling psychiatric conditions (depressive, bipolar, and personality disorders) and examining causes, mechanisms, and treatments for mood disorders.
|
9/17/2009
|
|
In Session with Sarah H. Lisanby, MD: Transcranial Magnetic Stimulation Therapy
|
Dr. Lisanby is professor of clinical psychiatry and Chief of the Division of Brain Stimulation and Therapeutic Modulation at Columbia University/New York State Psychiatric Institute, Director of the Brain Stimulation Service Line at New York Presbyterian Hospital, and head of the Transcranial Magnetic Stimulation Unit at the Program for Imaging and Cognitive Sciences, Department of Radiology, Columbia University, all in New York City. Her published works are on topics concerning TMS, magnetic seizure therapy, ECT, and depression, among others. Dr. Lisanby is the recipient of over 35 honors and awards, including the Gerald L. Klerman Award presented by the National Alliance for Research on Schizophrenia and Depression, and the Max Hamilton Memorial Prize of the Collegium Internationale Neuro-Psychoharmacologicum.
|
8/4/2009
|
|
In Session with Sarah H. Lisanby, MD: Transcranial Magnetic Stimulation Therapy
|
Dr. Lisanby is professor of clinical psychiatry and Chief of the Division of Brain Stimulation and Therapeutic Modulation at Columbia University/New York State Psychiatric Institute, Director of the Brain Stimulation Service Line at New York Presbyterian Hospital, and head of the Transcranial Magnetic Stimulation Unit at the Program for Imaging and Cognitive Sciences, Department of Radiology, Columbia University, all in New York City. Her published works are on topics concerning TMS, magnetic seizure therapy, ECT, and depression, among others. Dr. Lisanby is the recipient of over 35 honors and awards, including the Gerald L. Klerman Award presented by the National Alliance for Research on Schizophrenia and Depression, and the Max Hamilton Memorial Prize of the Collegium Internationale Neuro-Psychoharmacologicum.
|
8/4/2009
|
|
In Session with Wayne K. Goodman, MD: Deep Brain Stimulation
|
Dr. Goodman is chairman in the Department of Psychiatry at Mount Sinai School of Medicine in New York City. He previously served as director of the Division of Adult Translational Research and Treatment Development at the National Institute of Mental Health in Bethesda, Maryland. Dr. Goodman is a member of the American College of Neuropsychopharmacology, a distinguished fellow of the American Psychiatric Association, and member and past chair of the Food and Drug Administration’s Psychopharmacologic Drug Advisory Committee. A pioneering researcher in the field of obsessive-compulsive disorder (OCD), Dr. Goodman is the principal developer of the Yale-Brown Obsessive Compulsive Scale, the gold standard for assessing OCD.
|
7/2/2009
|
|
In Session with Wayne K. Goodman, MD: Deep Brain Stimulation
|
Dr. Goodman is chairman in the Department of Psychiatry at Mount Sinai School of Medicine in New York City. He previously served as director of the Division of Adult Translational Research and Treatment Development at the National Institute of Mental Health in Bethesda, Maryland. Dr. Goodman is a member of the American College of Neuropsychopharmacology, a distinguished fellow of the American Psychiatric Association, and member and past chair of the Food and Drug Administration’s Psychopharmacologic Drug Advisory Committee. A pioneering researcher in the field of obsessive-compulsive disorder (OCD), Dr. Goodman is the principal developer of the Yale-Brown Obsessive Compulsive Scale, the gold standard for assessing OCD.
|
7/2/2009
|
|
In Session with Marlene Freeman, MD: Omega-3 Fatty Acids: Complementary and Alternative Medicine in Psychiatry
|
Dr. Freeman is a lecturer at Harvard Medical School and staff psychiatrist at Massachusetts General Hospital in Boston. Her research and clinical interests focus on mood disorders in women. Her particular interest is in treatment research that takes into account patient preferences and safety for the perinatal period. This has led her to focus on integrative medicine strategies. Dr. Freeman also focuses on the accurate and broad dissemination of evidence-based information to healthcare providers and the public.
|
6/2/2009
|
|
In Session with Marlene Freeman, MD: Omega-3 Fatty Acids: Complementary and Alternative Medicine in Psychiatry
|
Dr. Freeman is a lecturer at Harvard Medical School and staff psychiatrist at Massachusetts General Hospital in Boston. Her research and clinical interests focus on mood disorders in women. Her particular interest is in treatment research that takes into account patient preferences and safety for the perinatal period. This has led her to focus on integrative medicine strategies. Dr. Freeman also focuses on the accurate and broad dissemination of evidence-based information to healthcare providers and the public.
|
6/2/2009
|
|
In Session with Steven L. Dubovsky, MD: The Risk/Benefit Comparison of Newer and Older Antipsychotics
|
Dr. Dubovsky is professor and chair of the Department of Psychiatry at the University of Buffalo in New York State and adjoint professor of Psychiatry and Medicine at the University of Colorado in Boulder. His research focuses on intracellular signaling in mood disorders, the pathophysiology of psychiatric illness, development of new treatments, and interactions between medical and psychiatric illnesses. Dr. Dubovsky maintains an active clinical practice devoted to mood disorders; complex and difficult clinical problems; and consultation to psychiatrists, other physicians, and other mental health professionals.
|
4/7/2009
|
|
In Session with Steven L. Dubovsky, MD: The Risk/Benefit Comparison of Newer and Older Antipsychotics
|
Dr. Dubovsky is professor and chair of the Department of Psychiatry at the University of Buffalo in New York State and adjoint professor of Psychiatry and Medicine at the University of Colorado in Boulder. His research focuses on intracellular signaling in mood disorders, the pathophysiology of psychiatric illness, development of new treatments, and interactions between medical and psychiatric illnesses. Dr. Dubovsky maintains an active clinical practice devoted to mood disorders; complex and difficult clinical problems; and consultation to psychiatrists, other physicians, and other mental health professionals.
|
4/7/2009
|
|
In Session with Andreas V. Alexopoulos, MD, MPH: Epilepsy
|
Dr. Alexopoulos is staff physician in the Epilepsy Center of the Neurological Institute at the Cleveland Clinic in Ohio. Previously, he served as chief resident in adult neurology at the Mount Sinai School of Medicine in New York City. Dr. Alexopoulos has twice received the Cleveland Clinic’s World Class Service Recognition Award. He is a member of the American Epilepsy Society, the Society of Neuroscience, and the American Clinical Neurophysiology Society, among others. His specialty interests include epilepsy, clinical neurophysiology, and translational research in epilepsy.
|
3/3/2009
|
|
In Session with Andreas V. Alexopoulos, MD, MPH: Epilepsy
|
Dr. Alexopoulos is staff physician in the Epilepsy Center of the Neurological Institute at the Cleveland Clinic in Ohio. Previously, he served as chief resident in adult neurology at the Mount Sinai School of Medicine in New York City. Dr. Alexopoulos has twice received the Cleveland Clinic’s World Class Service Recognition Award. He is a member of the American Epilepsy Society, the Society of Neuroscience, and the American Clinical Neurophysiology Society, among others. His specialty interests include epilepsy, clinical neurophysiology, and translational research in epilepsy.
|
3/3/2009
|
|
In Session with Jerome M. Siegel, PhD: Narcolepsy
|
Jerome M. Siegel, PhD, is professor of psychiatry at the University of California, Los Angeles, former president of the Sleep Research Society, and the recipient of Merit and Javits awards from the National Institutes of Health and the Distinguished Scientist award from the Sleep Research Society. His laboratory has made discoveries concerning the role of hypocretin in human narcolepsy and Parkinson’s disease. He has studied the phylogeny of sleep as a clue to sleep function, discovering that the primitive mammal platypus has rapid eye movement sleep and that marine mammals can go without extended periods of sleep for long periods without ill effects.
|
1/7/2009
|
|
In Session with Jerome M. Siegel, PhD: Narcolepsy
|
Jerome M. Siegel, PhD, is professor of psychiatry at the University of California, Los Angeles, former president of the Sleep Research Society, and the recipient of Merit and Javits awards from the National Institutes of Health and the Distinguished Scientist award from the Sleep Research Society. His laboratory has made discoveries concerning the role of hypocretin in human narcolepsy and Parkinson’s disease. He has studied the phylogeny of sleep as a clue to sleep function, discovering that the primitive mammal platypus has rapid eye movement sleep and that marine mammals can go without extended periods of sleep for long periods without ill effects.
|
1/7/2009
|
|
In Session with Diana O. Perkins, MD, MPH: Schizophrenia
|
Dr. Perkins is professor of psychiatry in the Department of Psychiatry at the University of North Carolina (UNC) School of Medicine in Chapel Hill. She is medical director of Outreach and Support Intervention Services at UNC Hospitals and the UNC-Chapel Hill School of Medicine. Dr. Perkins’ research emphasizes treatment of the prodromal period and early intervention of the first episode of schizophrenia. Currently investigating pharmacologic and psychotherapeutic treatments for psychosis, she focuses on managing side effects of atypical antipsychotics and the weight gain mechanism in patients taking psychotropic medications. In addition, Dr. Perkins is investigating the genetic basis of schizophrenia.
|
12/2/2008
|
|
In Session with Diana O. Perkins, MD, MPH: Schizophrenia
|
Dr. Perkins is professor of psychiatry in the Department of Psychiatry at the University of North Carolina (UNC) School of Medicine in Chapel Hill. She is medical director of Outreach and Support Intervention Services at UNC Hospitals and the UNC-Chapel Hill School of Medicine. Dr. Perkins’ research emphasizes treatment of the prodromal period and early intervention of the first episode of schizophrenia. Currently investigating pharmacologic and psychotherapeutic treatments for psychosis, she focuses on managing side effects of atypical antipsychotics and the weight gain mechanism in patients taking psychotropic medications. In addition, Dr. Perkins is investigating the genetic basis of schizophrenia.
|
12/2/2008
|
|
In Session with Dennis C. Turk, PhD: Fibromyalgia
|
Dr. Turk is John and Emma Bonica Professor of Anesthesiology and Pain Research and director of the Fibromyalgia Research Program at the University of Washington in Seattle, Washington. He is also editor-in-chief of The Clinical Journal of Pain and co-director of the Initiative on the Methods, Measurement, and Pain Assessment in Clinical Trials. While his research has been funded by the National Center for Health Statistics, National Center for Medical Rehabilitation Research, and numerous private foundations, he has consistently received funding from the National Institutes of Health since 1977. Dr. Turk has published over 450 journal articles and chapters in erudite texts and written and edited 13 volumes, including The Pain Survival Guide: How to Reclaim Your Life.
|
10/30/2008
|
|
In Session with Dennis C. Turk, PhD: Fibromyalgia
|
Dr. Turk is John and Emma Bonica Professor of Anesthesiology and Pain Research and director of the Fibromyalgia Research Program at the University of Washington in Seattle, Washington. He is also editor-in-chief of The Clinical Journal of Pain and co-director of the Initiative on the Methods, Measurement, and Pain Assessment in Clinical Trials. While his research has been funded by the National Center for Health Statistics, National Center for Medical Rehabilitation Research, and numerous private foundations, he has consistently received funding from the National Institutes of Health since 1977. Dr. Turk has published over 450 journal articles and chapters in erudite texts and written and edited 13 volumes, including The Pain Survival Guide: How to Reclaim Your Life.
|
10/30/2008
|
|
In Session with Samuel Gandy, MD, PhD: Alzheimer’s Disease
|
Samuel Gandy, MD, PhD, is Mount Sinai Professor of Alzheimer’s Disease Research, professor of neurology and psychiatry, associate director of the Mount Sinai Alzheimer’s Disease Research Center in New York City, and past chair of the National Medical and Scientific Advisory Council of the Alzheimer’s Association. As an international expert in the metabolism of amyloid that clogs the brain in patients with Alzheimer’s disease, Dr. Gandy has written over 150 original papers, chapters, and reviews on this topic. In 1989, he and his colleagues discovered medications that could lower the formation of amyloid. He has received continuous National Institutes of Health funding for his research on amyloid metabolism since 1986.
|
8/26/2008
|
|
In Session with Samuel Gandy, MD, PhD: Alzheimer’s Disease
|
Samuel Gandy, MD, PhD, is Mount Sinai Professor of Alzheimer’s Disease Research, professor of neurology and psychiatry, associate director of the Mount Sinai Alzheimer’s Disease Research Center in New York City, and past chair of the National Medical and Scientific Advisory Council of the Alzheimer’s Association. As an international expert in the metabolism of amyloid that clogs the brain in patients with Alzheimer’s disease, Dr. Gandy has written over 150 original papers, chapters, and reviews on this topic. In 1989, he and his colleagues discovered medications that could lower the formation of amyloid. He has received continuous National Institutes of Health funding for his research on amyloid metabolism since 1986.
|
8/26/2008
|
|
In Session with Neil E. Hutcher, MD: Bariatric Surgery
|
Dr. Hutcher serves on the advisory board of the American Obesity Association. As past president of the American Society for Metabolic and Bariatric Surgery, he is proactive in issues concerning insurance coverage and medical access for severely obese patients. He was chairman of the Department of Surgery at St. Mary’s Hospital and clinical associate professor at the Medical College of Virginia and the McGuire Veterans Administration Hospital in Richmond, Virginia. Dr. Hutcher’s current practice is devoted almost entirely to the surgical treatment of morbid obesity.
|
7/29/2008
|
|
In Session with Neil E. Hutcher, MD: Bariatric Surgery
|
Dr. Hutcher serves on the advisory board of the American Obesity Association. As past president of the American Society for Metabolic and Bariatric Surgery, he is proactive in issues concerning insurance coverage and medical access for severely obese patients. He was chairman of the Department of Surgery at St. Mary’s Hospital and clinical associate professor at the Medical College of Virginia and the McGuire Veterans Administration Hospital in Richmond, Virginia. Dr. Hutcher’s current practice is devoted almost entirely to the surgical treatment of morbid obesity.
|
7/29/2008
|
|
In Session with Andrea Allen, PhD: Cognitive-Behavioral Therapy for Obsessive-Compulsive Disorder
|
Dr. Allen is both assistant professor in the Department of Psychiatry at the Mount Sinai School of Medicine (MSSM) in New York City and director of psychological services at MSSM’s Center of Excellence in Compulsive and Impulsive Disorders. Her research interests primarily include the treatment of disorders within the obsessive-compulsive spectrum, including obsessive-compulsive disorder and body dysmorphic disorder. In addition, she trains psychiatrists and psychologists on these conditions. Dr. Allen is a widely published author of numerous original research publications and review articles.
|
6/26/2008
|
|
In Session with Andrea Allen, PhD: Cognitive-Behavioral Therapy for Obsessive-Compulsive Disorder
|
Dr. Allen is both assistant professor in the Department of Psychiatry at the Mount Sinai School of Medicine (MSSM) in New York City and director of psychological services at MSSM’s Center of Excellence in Compulsive and Impulsive Disorders. Her research interests primarily include the treatment of disorders within the obsessive-compulsive spectrum, including obsessive-compulsive disorder and body dysmorphic disorder. In addition, she trains psychiatrists and psychologists on these conditions. Dr. Allen is a widely published author of numerous original research publications and review articles.
|
6/26/2008
|
|
In Session with Sanjay J. Mathew, MD: Ketamine: New Pathways of Medication
|
Dr. Mathew is assistant professor of Psychiatry at the Mount Sinai School of Medicine (MSSM) in New York City. A board-certified psychiatrist, Dr. Mathew is also attending physician in the Mood and Anxiety Disorders Program at the Mount Sinai Medical Center. In 2007, he received the American Foundation for Suicide Prevention Pfizer Travel Award as well as the Lamport Research Award from MSSM. In addition to therapeutic approaches for treatment-resistant depression and anxiety, Dr. Mathew’s research involves magnetic resonance imaging and spectroscopy applications to anxiety and mood disorders.
|
5/30/2008
|
|
In Session with Sanjay J. Mathew, MD: Ketamine: New Pathways of Medication
|
Dr. Mathew is assistant professor of Psychiatry at the Mount Sinai School of Medicine (MSSM) in New York City. A board-certified psychiatrist, Dr. Mathew is also attending physician in the Mood and Anxiety Disorders Program at the Mount Sinai Medical Center. In 2007, he received the American Foundation for Suicide Prevention Pfizer Travel Award as well as the Lamport Research Award from MSSM. In addition to therapeutic approaches for treatment-resistant depression and anxiety, Dr. Mathew’s research involves magnetic resonance imaging and spectroscopy applications to anxiety and mood disorders.
|
5/30/2008
|
|
In Session with James D. King, MD: The Status of the Primary Care Field in Relation to Psychiatric Care
|
Dr. King is president of the American Academy of Family Physicians (AAFP), which respresents 94,000 physicians and medical students nationwide. He is volunteer faculty at the University of Tennessee Center for Health Sciences, Memphis, and medical director of Chester County Healthcare Services in Selmer. In 1997, Dr. King received the Family Physician of the Year Award from the Tennessee Academy of Family Physicians. As member of the board of directors of FamMedPAC, the AAFP’s political action committee, Dr. King advocates the legislative goals of family medicine to members of Congress.
|
4/29/2008
|
|
In Session with James D. King, MD: The Status of the Primary Care Field in Relation to Psychiatric Care
|
Dr. King is president of the American Academy of Family Physicians (AAFP), which respresents 94,000 physicians and medical students nationwide. He is volunteer faculty at the University of Tennessee Center for Health Sciences, Memphis, and medical director of Chester County Healthcare Services in Selmer. In 1997, Dr. King received the Family Physician of the Year Award from the Tennessee Academy of Family Physicians. As member of the board of directors of FamMedPAC, the AAFP’s political action committee, Dr. King advocates the legislative goals of family medicine to members of Congress.
|
4/29/2008
|
|
In Session with Susan J. Diem, MD, MPH: Depression, Antidepressants, and Bone Loss
|
Dr. Diem is assistant professor of medicine at the University of Minnesota. She is a general internist, epidemiologist, and clinical trialist of women’s health. In addition, her clinical practice is primarily focused on perimenopausal and postmenopausal women. Dr. Diem is co-investigator on the Study of Osteoporotic Fractures, a prospective cohort study funded by the National Institutes of Health that examines the risk factors for osteoporosis and fractures in postmenopausal women.
|
3/27/2008
|
|
In Session with Susan J. Diem, MD, MPH: Depression, Antidepressants, and Bone Loss
|
Dr. Diem is assistant professor of medicine at the University of Minnesota. She is a general internist, epidemiologist, and clinical trialist of women’s health. In addition, her clinical practice is primarily focused on perimenopausal and postmenopausal women. Dr. Diem is co-investigator on the Study of Osteoporotic Fractures, a prospective cohort study funded by the National Institutes of Health that examines the risk factors for osteoporosis and fractures in postmenopausal women.
|
3/27/2008
|
|
In Session with Anita H. Clayton, MD: An Update on the Sexual Side Effects of Medication
|
Dr. Clayton is David C. Wilson professor of psychiatry and professor of clinical obstetrics and gynecology at the University of Virginia in Charlottesville. She is distinguished fellow of the American Psychiatric Association and certified by the American Board of Psychiatry and Neurology. Dr. Clayton is consulting editor for the Journal of Sex & Marital Therapy and received the Columnist of the Year award in 2005 for her bi-monthly column in Primary Psychiatry, “Considerations in Women’s Mental Health.” In 2007, her book, Satisfaction: Women, Sex and the Quest for Intimacy, was published for the general public.
|
2/25/2008
|
|
In Session with Anita H. Clayton, MD: An Update on the Sexual Side Effects of Medication
|
Dr. Clayton is David C. Wilson professor of psychiatry and professor of clinical obstetrics and gynecology at the University of Virginia in Charlottesville. She is distinguished fellow of the American Psychiatric Association and certified by the American Board of Psychiatry and Neurology. Dr. Clayton is consulting editor for the Journal of Sex & Marital Therapy and received the Columnist of the Year award in 2005 for her bi-monthly column in Primary Psychiatry, “Considerations in Women’s Mental Health.” In 2007, her book, Satisfaction: Women, Sex and the Quest for Intimacy, was published for the general public.
|
2/25/2008
|
|
In Session with Philip G. Janicak, MD: Neuromodulation
|
Dr. Janicak is professor of Psychiatry at Rush University in Chicago, Illinois, medical director of the Rush Psychiatric Clinical Research Center, and distinguished fellow at the American Psychiatric Association. He has been listed in Best Doctors of America since 1996 and Who’s Who in America since 2002. In 2003, the Illinois chapter of the National Alliance for the Mentally Ill named Dr. Janicak “Psychiatrist of the Year.” With a strong interest in the assessment and treatment of mood and psychotic disorders, he has been a National Institute of Mental Health grant awardee as both principal and co-investigator. Dr. Janicak is editor of the Psychopharm Review and has authored >250 publications in psychiatric literature, including Principles and Practice of Psychopharmacotherapy
|
1/24/2008
|
|
In Session with Philip G. Janicak, MD: Neuromodulation
|
Dr. Janicak is professor of Psychiatry at Rush University in Chicago, Illinois, medical director of the Rush Psychiatric Clinical Research Center, and distinguished fellow at the American Psychiatric Association. He has been listed in Best Doctors of America since 1996 and Who’s Who in America since 2002. In 2003, the Illinois chapter of the National Alliance for the Mentally Ill named Dr. Janicak “Psychiatrist of the Year.” With a strong interest in the assessment and treatment of mood and psychotic disorders, he has been a National Institute of Mental Health grant awardee as both principal and co-investigator. Dr. Janicak is editor of the Psychopharm Review and has authored >250 publications in psychiatric literature, including Principles and Practice of Psychopharmacotherapy
|
1/24/2008
|
|
In Session with Benjamin J. Sadock, MD: The Comprehensive Textbook of Psychiatry, 8th Edition
|
Dr. Sadock is Menas S. Gregory professor of psychiatry and vice chairman at the New York University (NYU) School of Medicine. He is attending psychiatrist at the Bellevue and Tisch Hospitals and is consulting psychiatrist at Lenox Hill Hospital. Dr. Sadock is diplomate of the American Board of Psychiatry and Neurology and Distinguished Life Fellow of the American Psychiatric Association. He is also president and founder of the NYU-Bellevue Psychiatric Society. He was appointed Faculty Scholar at the NYU School of Medicine in 2000. Dr. Sadock is author and editor of over 100 publications and book reviewer for psychiatric journals, including the American Journal of Psychiatry.
|
12/27/2007
|
|
In Session with Benjamin J. Sadock, MD: The Comprehensive Textbook of Psychiatry, 8th Edition
|
Dr. Sadock is Menas S. Gregory professor of psychiatry and vice chairman at the New York University (NYU) School of Medicine. He is attending psychiatrist at the Bellevue and Tisch Hospitals and is consulting psychiatrist at Lenox Hill Hospital. Dr. Sadock is diplomate of the American Board of Psychiatry and Neurology and Distinguished Life Fellow of the American Psychiatric Association. He is also president and founder of the NYU-Bellevue Psychiatric Society. He was appointed Faculty Scholar at the NYU School of Medicine in 2000. Dr. Sadock is author and editor of over 100 publications and book reviewer for psychiatric journals, including the American Journal of Psychiatry.
|
12/27/2007
|
|
In Session with Michael E. Thase, MD: Examining the Strengths and Limitations of Generic Formulations
of Antidepressants
|
Dr. Thase is professor of psychiatry at the University of Pennsylvania School of Medicine in Philadelphia. He is a distinguished fellow of the American Psychiatric Association and a founding fellow of the Academy of Cognitive Therapy, a non-profit mental health organization dedicated to serving people with mental health disorders. He is director of the American Society of Clinical Psychopharmocology and vice chairman on the Scientific Advisory Board of the National Depression and Bipolar Support Alliance. Dr. Thase’s research centers on the evaluation and treatment of mood disorders.
|
11/28/2007
|
|
In Session with Michael E. Thase, MD: Examining the Strengths and Limitations of Generic Formulations
of Antidepressants
|
Dr. Thase is professor of psychiatry at the University of Pennsylvania School of Medicine in Philadelphia. He is a distinguished fellow of the American Psychiatric Association and a founding fellow of the Academy of Cognitive Therapy, a non-profit mental health organization dedicated to serving people with mental health disorders. He is director of the American Society of Clinical Psychopharmocology and vice chairman on the Scientific Advisory Board of the National Depression and Bipolar Support Alliance. Dr. Thase’s research centers on the evaluation and treatment of mood disorders.
|
11/28/2007
|
|
In Session with Joseph F. Goldberg, MD: Bipolar Disorder
|
Dr. Goldberg is director of the Affective Disorders Program at Silver Hill Hospital in New Canaan, Connecticut, and associate clinical professor of psychiatry at the Mount Sinai School of Medicine in New York City. His research focuses on the treatment and clinical features of bipolar disorder. He is a co-investigator in the National Institute of Mental Health (NIMH) Systematic Treatment Enhancement Program for Bipolar Disorder and has received a Career Development Award from the NIMH. He has also received research grants from the National Alliance for Research in Schizophrenia and Depression, the American Foundation for Suicide Prevention, and the Stanley Foundation.
|
10/29/2007
|
|
In Session with Joseph F. Goldberg, MD: Bipolar Disorder
|
Dr. Goldberg is director of the Affective Disorders Program at Silver Hill Hospital in New Canaan, Connecticut, and associate clinical professor of psychiatry at the Mount Sinai School of Medicine in New York City. His research focuses on the treatment and clinical features of bipolar disorder. He is a co-investigator in the National Institute of Mental Health (NIMH) Systematic Treatment Enhancement Program for Bipolar Disorder and has received a Career Development Award from the NIMH. He has also received research grants from the National Alliance for Research in Schizophrenia and Depression, the American Foundation for Suicide Prevention, and the Stanley Foundation.
|
10/29/2007
|
|
In Session with Stephen R. Marder, MD: Newer Antipsychotics and the Differences Between Clinical Experiences and Clinical Trials
|
Dr. Marder is professor at the Semel Institute of Neuroscience and Human Behavior at the University of California, Los Angeles (UCLA); director of the Veterans Integrated Service Network 22 Mental Illness Research, Education, and Clinical Center at the Department of Veterans Affairs in Los Angeles; and director of the Section on Psychosis at the UCLA Semel Institute. Dr. Marder’s research has focused on the treatment of schizophrenia and the pharmacology of antipsychotics.
|
9/24/2007
|
|
In Session with Stephen R. Marder, MD: Newer Antipsychotics and the Differences Between Clinical Experiences and Clinical Trials
|
Dr. Marder is professor at the Semel Institute of Neuroscience and Human Behavior at the University of California, Los Angeles (UCLA); director of the Veterans Integrated Service Network 22 Mental Illness Research, Education, and Clinical Center at the Department of Veterans Affairs in Los Angeles; and director of the Section on Psychosis at the UCLA Semel Institute. Dr. Marder’s research has focused on the treatment of schizophrenia and the pharmacology of antipsychotics.
|
9/24/2007
|
|
In Session with Naomi Wray, PhD: Anxiety and Comorbid Measures Associated with Plexin A2
|
Dr. Wray is a statistical geneticist specializing in the genetics of complex diseases. She is senior research officer at Queensland Institute of Medical Research in Brisbane, Australia, where she leads the Anxiety and Depression Study of the Genetic Epidemiology Laboratory. The study represents a powerful design to identify a large cohort of individuals for genetic analysis for whom comorbidity between depression and anxiety subtypes is fully documented.
|
8/29/2007
|
|
In Session with Naomi Wray, PhD: Anxiety and Comorbid Measures Associated with Plexin A2
|
Dr. Wray is a statistical geneticist specializing in the genetics of complex diseases. She is senior research officer at Queensland Institute of Medical Research in Brisbane, Australia, where she leads the Anxiety and Depression Study of the Genetic Epidemiology Laboratory. The study represents a powerful design to identify a large cohort of individuals for genetic analysis for whom comorbidity between depression and anxiety subtypes is fully documented.
|
8/29/2007
|
|
In Session with Jeffrey A. Lieberman, MD: Tardive Dyskinesia
|
Dr. Lieberman is the Lawrence E. Kolb Chairman of Psychiatry at the Columbia University College of Physicians and Surgeons and director of the New York State Psychiatric Institute in New York City. He also holds the Lieber Chair and directs the Lieber Center for Schizophrenia Research in the Department of Psychiatry at Columbia, and serves as the principal investigator of the Clinical Antipsychotic Trials of Intervention Effectiveness Research Program sponsored by the National Institute of Mental Health. Dr. Lieberman’s research focuses on the neurobiology, pharmacology, and treatment of schizophrenia and related psychotic disorders.
|
7/27/2007
|
|
In Session with Jeffrey A. Lieberman, MD: Tardive Dyskinesia
|
Dr. Lieberman is the Lawrence E. Kolb Chairman of Psychiatry at the Columbia University College of Physicians and Surgeons and director of the New York State Psychiatric Institute in New York City. He also holds the Lieber Chair and directs the Lieber Center for Schizophrenia Research in the Department of Psychiatry at Columbia, and serves as the principal investigator of the Clinical Antipsychotic Trials of Intervention Effectiveness Research Program sponsored by the National Institute of Mental Health. Dr. Lieberman’s research focuses on the neurobiology, pharmacology, and treatment of schizophrenia and related psychotic disorders.
|
7/27/2007
|
|
In Session with Darrel A. Regier, MD, MPH: The Developmental Process for the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
|
Dr. Regier is executive director of the American Psychiatric Institute for Research and Education and director of the Division of Research at the American Psychiatric Association. During his 25 years at the National Institute of Mental Health, Dr. Regier was involved with the World Health Organization in international programs on the classification of mental disorders. He currently serves as vice chair of the task force to develop the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.
|
6/26/2007
|
|
In Session with Darrel A. Regier, MD, MPH: The Developmental Process for the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
|
Dr. Regier is executive director of the American Psychiatric Institute for Research and Education and director of the Division of Research at the American Psychiatric Association. During his 25 years at the National Institute of Mental Health, Dr. Regier was involved with the World Health Organization in international programs on the classification of mental disorders. He currently serves as vice chair of the task force to develop the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.
|
6/26/2007
|
|
In Session with Russell T. Joffe, MD:
The Impact and Psychological Manifestations of Thyroid Dysfunction
|
Dr. Joffe is professor of psychiatry at the University of Medicine and Dentistry of New Jersey and staff psychiatrist at The University Hospital, both in Newark. Dr. Joffe has been listed in The Best Doctors in America in 2005–2006. His research interests include depression, bipolar disorder, and psychoneuroendocrinology.
|
5/26/2007
|
|
In Session with Russell T. Joffe, MD:
The Impact and Psychological Manifestations of Thyroid Dysfunction
|
Dr. Joffe is professor of psychiatry at the University of Medicine and Dentistry of New Jersey and staff psychiatrist at The University Hospital, both in Newark. Dr. Joffe has been listed in The Best Doctors in America in 2005–2006. His research interests include depression, bipolar disorder, and psychoneuroendocrinology.
|
5/26/2007
|
|
In Session with Michael B. Whitlow, MD, PhD: The Dermatological Side Effects of Pharmacologic Agents
|
Dr. Whitlow is a dermatologist in private practice, and clinical associate professor of dermatology at New York University Medical Center, both in New York City.
His clinical interests include allergic and immunologic skin disease.
|
4/23/2007
|
|
In Session with Michael B. Whitlow, MD, PhD: The Dermatological Side Effects of Pharmacologic Agents
|
Dr. Whitlow is a dermatologist in private practice, and clinical associate professor of dermatology at New York University Medical Center, both in New York City.
His clinical interests include allergic and immunologic skin disease.
|
4/23/2007
|
|
Are Anxiety and Depression Actually the Same Disorder?
|
The dilemmas facing clinicians who diagnose and treat psychiatric disorders are different than the issues that confront practitioners specializing in cardiology, endocrinology, hematology, gynecology, or virtually any other field of medicine. In the case of most mental disorders, causation has not been established, diagnosis is based on clusters of symptoms, and treatments have a tendency to be non-specific. For example, I have given and heard lectures over the years on the differential diagnosis of depression and anxiety. Typically, variation in the focus of these talks included distinguishing between anxiety symptoms associated with depression, coexisting anxiety and depression, and mixed anxiety-depression. Often, these disorder distinctions seemed forced, with many points of differentiation reflecting a greater degree of diagnostic certainty than appeared to exist in real-world clinical care. In both clinical and epidemiologic samples, major depressive disorder (MDD) and generalized anxiety disorder (GAD) display substantial comorbidity and/or symptom overlap.
|
3/27/2007
|
|
Are Anxiety and Depression Actually the Same Disorder?
|
The dilemmas facing clinicians who diagnose and treat psychiatric disorders are different than the issues that confront practitioners specializing in cardiology, endocrinology, hematology, gynecology, or virtually any other field of medicine. In the case of most mental disorders, causation has not been established, diagnosis is based on clusters of symptoms, and treatments have a tendency to be non-specific. For example, I have given and heard lectures over the years on the differential diagnosis of depression and anxiety. Typically, variation in the focus of these talks included distinguishing between anxiety symptoms associated with depression, coexisting anxiety and depression, and mixed anxiety-depression. Often, these disorder distinctions seemed forced, with many points of differentiation reflecting a greater degree of diagnostic certainty than appeared to exist in real-world clinical care. In both clinical and epidemiologic samples, major depressive disorder (MDD) and generalized anxiety disorder (GAD) display substantial comorbidity and/or symptom overlap.
|
3/27/2007
|
|
In Session with Eric M. Plakun, MD: The Impact of Suicide on Physicians
|
Dr. Plakun is director of admissions and professional relations, a treatment team leader, psychotherapy supervisor, a member of the management group of the Erik H. Erikson Institute for Education and Research, and co-principal investigator of a prospective study of treatment outcome that utilizes objective measures of psychodynamic constructs at the Austen Riggs Center in Stockbridge, Massachusetts. He is also a distinguished fellow of the American Psychiatric Association and chair of its Committee on Psychotherapy by Psychiatrists.
|
3/27/2007
|
|
In Session with Eric M. Plakun, MD: The Impact of Suicide on Physicians
|
Dr. Plakun is director of admissions and professional relations, a treatment team leader, psychotherapy supervisor, a member of the management group of the Erik H. Erikson Institute for Education and Research, and co-principal investigator of a prospective study of treatment outcome that utilizes objective measures of psychodynamic constructs at the Austen Riggs Center in Stockbridge, Massachusetts. He is also a distinguished fellow of the American Psychiatric Association and chair of its Committee on Psychotherapy by Psychiatrists.
|
3/27/2007
|
|
In Session with Andrew A. Nierenberg, MD: The Sequenced Treatment Alternatives to Relieve Depression Study: Recent Results
|
Dr. Nierenberg is associate director of the Depression Clinical and Research Program at Massachusetts General Hospital and associate professor of psychiatry at Harvard Medical School in Boston. He is also director of the National Institute of Mental Health Bipolar Trials Network, a federally-funded infrastructure for the next generation of clinical trials to help patients with bipolar disorder. He was the site principal investigator for the Systematic Treatment Enhancement Program for Bipolar Disorder and was involved in the Sequenced Treatment Alternatives to Relieve Depression study. His research interests focus on bipolar disorder, treatment-resistant depression, and the longitudinal course of affective disorders. Dr. Nierenberg has been listed in The Best Doctors in America for the treatment of mood and anxiety disorders in every edition since 1994.
|
1/29/2007
|
|
In Session with Andrew A. Nierenberg, MD: The Sequenced Treatment Alternatives to Relieve Depression Study: Recent Results
|
Dr. Nierenberg is associate director of the Depression Clinical and Research Program at Massachusetts General Hospital and associate professor of psychiatry at Harvard Medical School in Boston. He is also director of the National Institute of Mental Health Bipolar Trials Network, a federally-funded infrastructure for the next generation of clinical trials to help patients with bipolar disorder. He was the site principal investigator for the Systematic Treatment Enhancement Program for Bipolar Disorder and was involved in the Sequenced Treatment Alternatives to Relieve Depression study. His research interests focus on bipolar disorder, treatment-resistant depression, and the longitudinal course of affective disorders. Dr. Nierenberg has been listed in The Best Doctors in America for the treatment of mood and anxiety disorders in every edition since 1994.
|
1/29/2007
|
|
In Session with Richard H. Weisler, MD: Treatment of Attention-Deficit/Hyperactivity Disorder
|
Dr. Weisler is adjunct professor of psychiatry at the University of North Carolina School of Medicine at Chapel Hill and adjunct associate professor of psychiatry and behavioral sciences at Duke University Medical Center in Durham. Also a private practitioner in Raleigh, North Carolina, Dr. Weisler has been a principal investigator in more than 200 clinical studies and was named one of America’s top psychiatrists for 2002–2003 by the Consumers’ Research Council of America. Dr. Weisler is currently working on a project with the Agency for Toxic Substances and Disease Registry/Centers for Disease Control and Prevention to improve recognition and knowledge of disaster mental health for healthcare providers in the wake of Hurricanes Katrina and Rita.
|
12/27/2006
|
|
In Session with Richard H. Weisler, MD: Treatment of Attention-Deficit/Hyperactivity Disorder
|
Dr. Weisler is adjunct professor of psychiatry at the University of North Carolina School of Medicine at Chapel Hill and adjunct associate professor of psychiatry and behavioral sciences at Duke University Medical Center in Durham. Also a private practitioner in Raleigh, North Carolina, Dr. Weisler has been a principal investigator in more than 200 clinical studies and was named one of America’s top psychiatrists for 2002–2003 by the Consumers’ Research Council of America. Dr. Weisler is currently working on a project with the Agency for Toxic Substances and Disease Registry/Centers for Disease Control and Prevention to improve recognition and knowledge of disaster mental health for healthcare providers in the wake of Hurricanes Katrina and Rita.
|
12/27/2006
|
|
In Session with J. Craig Nelson, MD: Treating Late-Life Depression
|
Dr. Nelson is professor of psychiatry, director of geriatric psychiatry, and holds the Leon J. Epstein, MD, chair in geriatric psychiatry at the University of California, San Francisco. His research and expertise focus principally on the description and treatment of adult and geriatric depression, as well as the psychopharmacology of antidepressants. Among many accomplishments, Dr. Nelson received the Yale Residents Outstanding Teacher award in 1995 and 2001, and the Distinguished Yale Alumni Award in 2006. He wrote Geriatric Psychopharmacology in 1998. Dr. Nelson was one of the founding members of the American Society of Clinical Psychopharmacology and served as its president from 1999 to 2003.
|
11/30/2006
|
|
In Session with J. Craig Nelson, MD: Treating Late-Life Depression
|
Dr. Nelson is professor of psychiatry, director of geriatric psychiatry, and holds the Leon J. Epstein, MD, chair in geriatric psychiatry at the University of California, San Francisco. His research and expertise focus principally on the description and treatment of adult and geriatric depression, as well as the psychopharmacology of antidepressants. Among many accomplishments, Dr. Nelson received the Yale Residents Outstanding Teacher award in 1995 and 2001, and the Distinguished Yale Alumni Award in 2006. He wrote Geriatric Psychopharmacology in 1998. Dr. Nelson was one of the founding members of the American Society of Clinical Psychopharmacology and served as its president from 1999 to 2003.
|
11/30/2006
|
|
In Session with Kimberly A. Yonkers, MD: Treating Depression in Pregnancy
|
Dr. Yonkers is associate professor in the Departments of Psychiatry and Obstetrics, Gynecology, and Reproductive Sciences, and an instructor in the Division of Epidemiology at Yale School of Medicine in New Haven. She is on the editorial boards of Archives of Women’s Health and Maternal and Child Health Journal. Dr. Yonkers is an ad hoc reviewer for the National Institutes of Health, president-elect of the North American Society of Psychosocial Obstetrics & Gynecology, and secretary of the International Association for Women’s Mental Health. Among her most recent honors, Dr. Yonkers was named among the “Best Doctors” from 2001–2005 in both the New York metro area and the United States.
|
10/27/2006
|
|
In Session with Kimberly A. Yonkers, MD: Treating Depression in Pregnancy
|
Dr. Yonkers is associate professor in the Departments of Psychiatry and Obstetrics, Gynecology, and Reproductive Sciences, and an instructor in the Division of Epidemiology at Yale School of Medicine in New Haven. She is on the editorial boards of Archives of Women’s Health and Maternal and Child Health Journal. Dr. Yonkers is an ad hoc reviewer for the National Institutes of Health, president-elect of the North American Society of Psychosocial Obstetrics & Gynecology, and secretary of the International Association for Women’s Mental Health. Among her most recent honors, Dr. Yonkers was named among the “Best Doctors” from 2001–2005 in both the New York metro area and the United States.
|
10/27/2006
|
|
In Session with Paul Daniel Arnold, MD, FRCPC: Glutamate Transporter Genes and Obsessive-Compulsive Disorder
|
Dr. Arnold is currently a scientist-track investigator and staff psychiatrist at the Hospital for Sick Children in Toronto, Canada. His research activities focus on the molecular genetics of early-onset obsessive-compulsive disorder (OCD). Dr. Arnold’s clinical work involves the assessment and treatment of children with OCD and obsessive-compulsive spectrum disorders. He has received numerous awards in recognition for his work, including the Career Development Award of the Anxiety Disorders Association of America and the Government of Ontario/Gregory M. Brown Graduate Scholarship in Science and Technology.
|
10/4/2006
|
|
In Session with Paul Daniel Arnold, MD, FRCPC: Glutamate Transporter Genes and Obsessive-Compulsive Disorder
|
Dr. Arnold is currently a scientist-track investigator and staff psychiatrist at the Hospital for Sick Children in Toronto, Canada. His research activities focus on the molecular genetics of early-onset obsessive-compulsive disorder (OCD). Dr. Arnold’s clinical work involves the assessment and treatment of children with OCD and obsessive-compulsive spectrum disorders. He has received numerous awards in recognition for his work, including the Career Development Award of the Anxiety Disorders Association of America and the Government of Ontario/Gregory M. Brown Graduate Scholarship in Science and Technology.
|
10/4/2006
|
|
In Session with David A. Lewis, MD: Cognition in Schizophrenia
|
Dr. Lewis is director of the Translational Neuroscience Program in the Department of Psychiatry, director of the National Institute of Mental Health Conte Center for the Neuroscience of Mental Disorders, and professor in the Departments of Psychiatry and Neuroscience at the University of Pittsburgh in Pennsylvania. He is also associate director of basic research at the Western Psychiatric Institute and Clinic in Pittsburgh. Dr. Lewis is associate editor of the Encyclopedia of Neuroscience, section editor of Neuroscience, and deputy editor of the American Journal of Psychiatry, and serves on numerous editorial boards. Among his most recent honors, Dr. Lewis received the Bristol-Myers Squibb Foundation Freedom to Discover Grant in Neuroscience, as well as the National Alliance for Research on Schizophrenia and Depression Lieber Prize.
|
8/31/2006
|
|
In Session with David A. Lewis, MD: Cognition in Schizophrenia
|
Dr. Lewis is director of the Translational Neuroscience Program in the Department of Psychiatry, director of the National Institute of Mental Health Conte Center for the Neuroscience of Mental Disorders, and professor in the Departments of Psychiatry and Neuroscience at the University of Pittsburgh in Pennsylvania. He is also associate director of basic research at the Western Psychiatric Institute and Clinic in Pittsburgh. Dr. Lewis is associate editor of the Encyclopedia of Neuroscience, section editor of Neuroscience, and deputy editor of the American Journal of Psychiatry, and serves on numerous editorial boards. Among his most recent honors, Dr. Lewis received the Bristol-Myers Squibb Foundation Freedom to Discover Grant in Neuroscience, as well as the National Alliance for Research on Schizophrenia and Depression Lieber Prize.
|
8/31/2006
|
|
In Session with Dennis S. Charney, MD: Resilience to Stress
|
Dr. Charney is dean of Academic and Scientific Affairs at Mount Sinai School of Medicine (MSSM) and senior vice president for Health Sciences at the Mount Sinai Medical Center in New York City. He is also Anne and Joel Ehrenkranz Professor in the Departments of Psychiatry, Neuroscience, Pharmacology, and Biochemistry at MSSM. Editor of several major textbooks and a member of numerous editorial boards, Dr. Charney is editor in chief of Biological Psychiatry. Dr. Charney is one of the foremost investigators in the neurobiology and treatment of mood and anxiety disorders. He has made fundamental contributions to the understanding of neural circuits, neurochemistry, and functional neuroanatomy of the regulation of mood and anxiety and the psychobiologic mechanisms of human resilience to stress. In addition, his research group has focused on the discovery of novel and more effective treatments for mood and anxiety disorders.
|
8/6/2006
|
|
In Session with Dennis S. Charney, MD: Resilience to Stress
|
Dr. Charney is dean of Academic and Scientific Affairs at Mount Sinai School of Medicine (MSSM) and senior vice president for Health Sciences at the Mount Sinai Medical Center in New York City. He is also Anne and Joel Ehrenkranz Professor in the Departments of Psychiatry, Neuroscience, Pharmacology, and Biochemistry at MSSM. Editor of several major textbooks and a member of numerous editorial boards, Dr. Charney is editor in chief of Biological Psychiatry. Dr. Charney is one of the foremost investigators in the neurobiology and treatment of mood and anxiety disorders. He has made fundamental contributions to the understanding of neural circuits, neurochemistry, and functional neuroanatomy of the regulation of mood and anxiety and the psychobiologic mechanisms of human resilience to stress. In addition, his research group has focused on the discovery of novel and more effective treatments for mood and anxiety disorders.
|
8/6/2006
|
|
In Session with Dolores Malaspina, MD, MSPH: Impact of Childhood Trauma on Psychiatric Illness
|
Dr. Malaspina is professor of psychiatry at Columbia University College of Physicians and Surgeons, and director of the Medical Genetics Division of Clinical Neurobiology at New York State Psychiatric Institute in New York City. Her research concerns the neurobiology and heterogeneity of schizophrenia. She has published more than 150 scientific contributions and is a reviewer for research grants and numerous psychiatric journals. Dr. Malaspina has received the Exemplary Psychiatrist Award from the National Alliance for the Mentally Ill, the NARSAD Ritter Award, and the Research Award from the New York State Office of Mental Health. She is a fellow of the American College of Neuropsychopharmacology and is a distinguished fellow of the American Psychiatric Association.
|
6/29/2006
|
|
In Session with Dolores Malaspina, MD, MSPH: Impact of Childhood Trauma on Psychiatric Illness
|
Dr. Malaspina is professor of psychiatry at Columbia University College of Physicians and Surgeons, and director of the Medical Genetics Division of Clinical Neurobiology at New York State Psychiatric Institute in New York City. Her research concerns the neurobiology and heterogeneity of schizophrenia. She has published more than 150 scientific contributions and is a reviewer for research grants and numerous psychiatric journals. Dr. Malaspina has received the Exemplary Psychiatrist Award from the National Alliance for the Mentally Ill, the NARSAD Ritter Award, and the Research Award from the New York State Office of Mental Health. She is a fellow of the American College of Neuropsychopharmacology and is a distinguished fellow of the American Psychiatric Association.
|
6/29/2006
|
|
In Session with Phillip J. Resnick, MD: Malingering of Psychiatric Symptoms
|
Dr. Resnick is director of the Division of Forensic Psychiatry at Case Western University School of Medicine and adjunct professor at Case Western University School of Law. He is also director of the Fellowship in Forensic Psychiatry at Case Western Reserve University and director of the Court Psychiatric Clinic in Cleveland.
|
6/7/2006
|
|
In Session with Phillip J. Resnick, MD: Malingering of Psychiatric Symptoms
|
Dr. Resnick is director of the Division of Forensic Psychiatry at Case Western University School of Medicine and adjunct professor at Case Western University School of Law. He is also director of the Fellowship in Forensic Psychiatry at Case Western Reserve University and director of the Court Psychiatric Clinic in Cleveland.
|
6/7/2006
|
|
In Session with S. Nassir Ghaemi, MD, MPH: The Use of Antidepressants in Bipolar Patients
|
The empirical evidence for the separate categories of bipolar and unipolar disorder was mostly based on genetic studies in the 1960s, which seemed to suggest a differentiation. Also, during that time there was the development of lithium, which people thought was specific for mania; tricyclic antidepressants (TCAs), which were specific for depression; and neuroleptics, which were specific for schizophrenia. However, now it is fairly clear that these drugs are relatively nonspecific diagnostically, and that genetic differences are not clear-cut.
|
5/26/2006
|
|
In Session with S. Nassir Ghaemi, MD, MPH: The Use of Antidepressants in Bipolar Patients
|
The empirical evidence for the separate categories of bipolar and unipolar disorder was mostly based on genetic studies in the 1960s, which seemed to suggest a differentiation. Also, during that time there was the development of lithium, which people thought was specific for mania; tricyclic antidepressants (TCAs), which were specific for depression; and neuroleptics, which were specific for schizophrenia. However, now it is fairly clear that these drugs are relatively nonspecific diagnostically, and that genetic differences are not clear-cut.
|
5/26/2006
|
|
In Session with Wayne K. Goodman, MD: Obsessive-Compulsive Disorder
|
Since I started treating and researching OCD, my colleagues and I have assumed that OCD is heterogeneous. We have searched for different homogeneous subtypes that could be based upon clinical characteristics or biologic markers.
|
5/25/2006
|
|
In Session with Wayne K. Goodman, MD: Obsessive-Compulsive Disorder
|
Since I started treating and researching OCD, my colleagues and I have assumed that OCD is heterogeneous. We have searched for different homogeneous subtypes that could be based upon clinical characteristics or biologic markers.
|
5/25/2006
|
|
In Session with Judith S. Beck, PhD: Cognitive-Behavioral Therapy
|
Dr. Beck is director of the Beck Institute for Cognitive Therapy and Research in Philadelphia and president and distinguished founding fellow of the Academy of Cognitive Therapy. She is also clinical associate professor of psychology in the Department of Psychiatry at the University of Pennsylvania in Philadelphia. She is the author of a basic text in the field, Cognitive Therapy: Basics and Beyond, which has been translated into 12 languages. Her other books include Cognitive Therapy for Challenging Problems: What to Do When the Basics Don’t Work, Cognitive Therapy for Personality Disorders, and the Oxford Textbook of Psychotherapy.
|
3/29/2006
|
|
In Session with Judith S. Beck, PhD: Cognitive-Behavioral Therapy
|
Dr. Beck is director of the Beck Institute for Cognitive Therapy and Research in Philadelphia and president and distinguished founding fellow of the Academy of Cognitive Therapy. She is also clinical associate professor of psychology in the Department of Psychiatry at the University of Pennsylvania in Philadelphia. She is the author of a basic text in the field, Cognitive Therapy: Basics and Beyond, which has been translated into 12 languages. Her other books include Cognitive Therapy for Challenging Problems: What to Do When the Basics Don’t Work, Cognitive Therapy for Personality Disorders, and the Oxford Textbook of Psychotherapy.
|
3/29/2006
|
|
In Session with Eric Hollander, MD
|
Dr. Hollander is professor of psychiatry; director of the Compulsive, Impulsive, and Anxiety Disorders Program; director of clinical psychopharmacology; and director of the Seaver and New York Autism Center of Excellence at Mount Sinai School of Medicine in New York City. He has received a Research Scientist Development Award from the National Institute of Mental Health to investigate the psychobiology of obsessive-compulsive disorder and related disorders, such as body dysmorphic disorder and pathological gambling. His other research interests include autism, neuropsychiatry, and functional imaging.
|
3/25/2006
|
|
In Session with Eric Hollander, MD
|
Dr. Hollander is professor of psychiatry; director of the Compulsive, Impulsive, and Anxiety Disorders Program; director of clinical psychopharmacology; and director of the Seaver and New York Autism Center of Excellence at Mount Sinai School of Medicine in New York City. He has received a Research Scientist Development Award from the National Institute of Mental Health to investigate the psychobiology of obsessive-compulsive disorder and related disorders, such as body dysmorphic disorder and pathological gambling. His other research interests include autism, neuropsychiatry, and functional imaging.
|
3/25/2006
|
|
In Session with Philip Seeman, MD, PhD: Psychopharmacology of Dopamine in Clinical Practice
|
There are unquestionably many primary defects that can cause psychotic signs and symptoms, particularly in schizophrenia, but we are now finding that they all converge on the dopamine system, both from a cause and treatment point of view.
|
2/24/2006
|
|
In Session with Philip Seeman, MD, PhD: Psychopharmacology of Dopamine in Clinical Practice
|
There are unquestionably many primary defects that can cause psychotic signs and symptoms, particularly in schizophrenia, but we are now finding that they all converge on the dopamine system, both from a cause and treatment point of view.
|
2/24/2006
|